Clinical Guideline

dexamethasone

Policy developed by: SA Maternal & Neonatal Clinical Network
Approved SA Health Safety & Quality Strategic Governance Committee on:
12 August 2014
Next review due: 31 Aug 2017

Summary
Clinical practice guideline for the administration of dexamethasone to a neonate

Keywords
Dexamethasone, bronchopulmonary dysplasia, extubation, infection, hypertension, hypokalaemia, hyperglycaemia, dyslipidaemia, osteoporosis, fractures, dyspepsia, bruising, hirsutism, growth retardation, myopathy, muscle wasting, cushingoid, weight gain, cataracts, osteonecrosis, osular hypertension, glaucoma, peptic ulceration, hypersensitivity, tendon, rupture, sepsis, gastric ulceration, ibuprofen, hydrocortisone, cortisone acetate, hydrocortisone, methylprednisolone, prednisolone, clinical guideline

Policy history
Is this a new policy? N
Does this policy amend or update an existing policy? Y
Does this policy replace an existing policy? Y
If so, which policies? dexamethasone

Applies to
All SA Health Portfolio
All Department for Health and Ageing Divisions
All Health Networks
CALHN, SALHN, NALHN, CHSALHN, WCHN, SAAS
Other

Staff impact
All Staff, Management, Admin, Students, Volunteers
All Clinical, Medical, Nursing, Allied Health, Emergency, Dental, Mental Health, Pathology

PDS reference CG023

Version control and change history

<table>
<thead>
<tr>
<th>Version</th>
<th>Date from</th>
<th>Date to</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>November 2012</td>
<td>17 June 2014</td>
<td>Original version</td>
</tr>
<tr>
<td>2.0</td>
<td>17 June 2014</td>
<td>12 Aug 2014</td>
<td>review</td>
</tr>
<tr>
<td>3.0</td>
<td>12 Aug 2014</td>
<td>current</td>
<td></td>
</tr>
</tbody>
</table>
dexamethasone
4mg/mL injection, 1mg/mL oral syrup*

© Department of Health, Government of South Australia. All rights reserved

Note

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Dose and Indications

Bronchopulmonary Dysplasia

Facilitating Extubation

Intravenous, Intramuscular or Oral
0.05 to 0.1mg/kg/dose twice a day.

Dose and duration of treatment are dependent on clinical response and directed by a neonatologist.

Treatment of post-intubation laryngeal oedema

Intravenous or Oral
0.2mg/kg/dose given 8 hourly for three doses (to be started at least 4 hours and preferable 12 hours prior to tube removal)

Endorsed by: South Australian Maternal & Neonatal Clinical Network
Last Revised: 12/08/2014
Contact: South Australian Neonatal Medication Guidelines Workgroup at: NeoMed@health.sa.gov.au
Preparation and Administration

**Intravenous for doses less than 0.4mg**

Dilute 1mL of the 4mg/mL dexamethasone sodium phosphate injection with 7mL sodium chloride 0.9% (to a total volume of 8mL). The resulting solution contains 0.5mg/mL dexamethasone.

<table>
<thead>
<tr>
<th>Dose</th>
<th>0.05mg</th>
<th>0.1mg</th>
<th>0.15mg</th>
<th>0.2mg</th>
<th>0.25mg</th>
<th>0.3mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.1mL</td>
<td>0.2mL</td>
<td>0.3mL</td>
<td>0.4mL</td>
<td>0.5mL</td>
<td>0.6mL</td>
</tr>
</tbody>
</table>

To be administered as a slow push over at least 3 minutes

Discard any remaining solution.

**Intravenous for doses greater than 0.4mg**

Use undiluted dexamethasone sodium phosphate injection (4mg/mL)

<table>
<thead>
<tr>
<th>Dose</th>
<th>0.4mg</th>
<th>0.8mg</th>
<th>1.2mg</th>
<th>1.6mg</th>
<th>2mg</th>
<th>2.4mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.1mL</td>
<td>0.2mL</td>
<td>0.3mL</td>
<td>0.4mL</td>
<td>0.5mL</td>
<td>0.6mL</td>
</tr>
</tbody>
</table>

To be administered as a slow push over at least 3 minutes

Discard any remaining solution.

**Oral**

Oral dexamethasone solution contains 1mg/mL.

Oral dexamethasone doses only require dilution when small doses are administered to ensure accuracy of dose.

Dilute 0.5mL of dexamethasone oral solution (1mg/mL) with 4.5mL of water for irrigation (to a total volume of 5mL). The resulting solution contains 0.1mg/mL

<table>
<thead>
<tr>
<th>Dose</th>
<th>0.04mg</th>
<th>0.06mg</th>
<th>0.08mg</th>
<th>0.1mg</th>
<th>0.12mg</th>
<th>0.14mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.4mL</td>
<td>0.6mL</td>
<td>0.8mL</td>
<td>1mL</td>
<td>1.2mL</td>
<td>1.4mL</td>
</tr>
</tbody>
</table>

Give with or after feeds to minimise gastrointestinal irritation

Discard remaining diluted solution

**Compatible Fluids**

Glucose 5%, sodium chloride 0.9%
**dexamethasone**

4mg/mL injection, 1mg/mL oral syrup*

**Adverse Effects**

These occur when dexamethasone is used at pharmacological doses. The incidence of adverse effects is related to dose and duration of treatment.

**Common**

Adrenal suppression\(^1\), increased susceptibility to infection, masking of signs of infection, sodium and water retention, hypertension, hypokalaemia, hyperglycaemia, dyslipidaemia, osteoporosis, fractures, dyspepsia, delayed wound healing, skin atrophy, bruising, hirsutism, growth retardation, myopathy, muscle wasting, cushingoid appearance, weight gain, cataracts

**Infrequent**

Osteonecrosis, particularly of the femoral and humeral heads, ocular hypertension, glaucoma

**Rare**

Peptic ulceration, hypersensitivity reactions, tendon rupture (especially of the Achilles tendon)

**Monitoring**

> Monitor for hypertension, hyperglycaemia and sepsis as per local unit protocol

**Practice Points**

> *Oral syrup is prepared at Women’s & Children’s Health Network Pharmacy. If not available the injection solution may be given orally (please note that these solutions are of different concentrations)

> Caution with use in the following patient groups: gastric ulceration, hypertension, concurrent use of indomethacin/ibuprofen, renal impairment or cardiac disease

> If an infant has been on dexamethasone in the last month, cover for possible adrenal suppression during subsequent episodes of stress with IV hydrocortisone

**Steroid equivalents (glucocorticoid activity)**

<table>
<thead>
<tr>
<th>Steroid</th>
<th>Equivalent in mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortisone Acetate</td>
<td>5mg</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>0.15mg</td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>4mg</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>0.8mg</td>
</tr>
<tr>
<td>Prednisolone / Prednisone</td>
<td>1mg</td>
</tr>
</tbody>
</table>

\(^1\) Acute cardiovascular collapse may occur when corticosteroids are abruptly stopped or if adrenal response is inadequate in periods of stress such as infection, trauma, surgery and blood loss.
dexamethasone
4mg/mL injection, 1mg/mL oral syrup*

Reference

1. Doyle LW, Davis PG, Morley CJ et al. DART Study Investigators: Low dose
dexamethasone facilitates extubation among chronically ventilator dependant infants: a
multicentre international randomized, controlled trial. Pediatrics 2006; 117:75-83

Version control and change history

PDS reference: OCE use only

<table>
<thead>
<tr>
<th>Version</th>
<th>Date from</th>
<th>Date to</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>November 2012</td>
<td>17 June 2014</td>
<td>Original version</td>
</tr>
<tr>
<td>2.0</td>
<td>17 June 2014</td>
<td>12 Aug 2014</td>
<td>review</td>
</tr>
<tr>
<td>3.0</td>
<td>12 Aug 2014</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Endorsed by:
South Australian Maternal & Neonatal Clinical Network

Last Revised:
12/08/2014

Contact:
NeoMed@health.sa.gov.au